Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Stake Trimmed by Samsara BioCapital LLC

Samsara BioCapital LLC lowered its stake in Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) by 43.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,110,913 shares of the biopharmaceutical company’s stock after selling 1,639,087 shares during the quarter. Sunesis Pharmaceuticals makes up 1.0% of Samsara BioCapital LLC’s investment portfolio, making the stock its 15th largest holding. Samsara BioCapital LLC owned about 2.91% of Sunesis Pharmaceuticals worth $1,534,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Aisling Capital Management LP lifted its holdings in shares of Sunesis Pharmaceuticals by 192.3% during the 1st quarter. Aisling Capital Management LP now owns 7,600,000 shares of the biopharmaceutical company’s stock valued at $9,234,000 after buying an additional 5,000,000 shares during the last quarter. Fosun International Ltd acquired a new position in shares of Sunesis Pharmaceuticals during the first quarter worth approximately $863,000. Vanguard Group Inc. lifted its holdings in shares of Sunesis Pharmaceuticals by 228.0% during the second quarter. Vanguard Group Inc. now owns 2,283,383 shares of the biopharmaceutical company’s stock worth $1,660,000 after buying an additional 1,587,157 shares during the last quarter. BlackRock Inc. increased its position in shares of Sunesis Pharmaceuticals by 257.3% during the second quarter. BlackRock Inc. now owns 783,059 shares of the biopharmaceutical company’s stock valued at $569,000 after purchasing an additional 563,924 shares during the period. Finally, Northern Trust Corp increased its position in shares of Sunesis Pharmaceuticals by 54.8% during the second quarter. Northern Trust Corp now owns 165,769 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 58,653 shares during the period. 32.85% of the stock is currently owned by hedge funds and other institutional investors.

In related news, major shareholder Aisling Capital Iv, Lp purchased 2,500,000 shares of the stock in a transaction on Monday, July 15th. The shares were purchased at an average cost of $0.60 per share, for a total transaction of $1,500,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 4.22% of the company’s stock.

A number of research firms have recently issued reports on SNSS. HC Wainwright restated a “hold” rating and set a $1.50 price objective on shares of Sunesis Pharmaceuticals in a research report on Friday, August 9th. ValuEngine upgraded Sunesis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Cowen restated a “hold” rating on shares of Sunesis Pharmaceuticals in a research report on Sunday, June 16th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $2.92.

Shares of SNSS traded down $0.01 on Wednesday, reaching $0.84. 18,090 shares of the stock traded hands, compared to its average volume of 446,149. The firm has a market cap of $94.62 million, a price-to-earnings ratio of -1.12 and a beta of 2.74. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.27 and a quick ratio of 2.27. Sunesis Pharmaceuticals, Inc. has a 12 month low of $0.20 and a 12 month high of $2.26. The stock’s 50-day moving average price is $0.85 and its 200-day moving average price is $0.96.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. As a group, equities research analysts forecast that Sunesis Pharmaceuticals, Inc. will post -0.4 earnings per share for the current fiscal year.

Sunesis Pharmaceuticals Profile

Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.

Recommended Story: What is total return in investing?

Want to see what other hedge funds are holding SNSS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS).

Institutional Ownership by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.